Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance

Fulgent Genetics, Inc.

GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).
Revenue $71.1M; GAAP gross margin 30.2%, non-GAAP gross margin 32.3%.
Adjusted EBITDA loss of $15.2M in Q1 2026.
Cash, equivalents, restricted cash & marketable securities $604.7M; expects ~$106M tax refund.
Bought back ~2.6M shares for $40.1M in Q1; FY2026 revenue guidance reaffirmed.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Fulgent Genetics, Inc. reported first quarter ended March 31, 2026 results: revenue 71.1 million, net income -24.8 million, EPS -0.80. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: 71.1 million
Net income: -24.8 million
EPS: -0.80
Guidance: reaffirmed
Result: reported results

Exact text from the filing

for fiscal year 2026 • Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash • Revenue of $71.1 million • GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% • GAAP loss of $24.8 million, or

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-199061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.